SPY414.92-5.67 -1.35%
DIA332.96-5.20 -1.54%
IXIC14,030.38-130.97 -0.92%

Morgan Stanley Maintains Underweight on Editas Medicine, Lowers Price Target to $37

Morgan Stanley maintains Editas Medicine (NASDAQ:EDIT) with a Underweight and lowers the price target from $40 to $37.

05/10/2021 08:59
Morgan Stanley maintains Editas Medicine (NASDAQ:EDIT) with a Underweight and lowers the price target from $40 to $37.